Navigation Links
Detke Joins MedAvante as Chief Medical Officer
Date:3/12/2009

Former Eli Lilly executive Michael J. Detke, MD, PhD, is frequent presenter on the causes of failed clinical studies for central nervous system (CNS) therapeutics and methods for improvement

HAMILTON, N.J., March 12 /PRNewswire/ -- MedAvante, Inc. the leader in centralized psychiatric patient evaluation, announced today that Michael Detke, MD, PhD, has joined the company as Chief Medical Officer and Director of the MedAvante Research Institute. Dr. Detke comes to MedAvante from Eli Lilly, Inc., in Indianapolis, Indiana, where he was Executive Director and head of early phase development of CNS therapeutics.

"We are honored to have Michael join our team," says Paul Gilbert, Chief Executive Officer of MedAvante. "At Lilly, Mike led early phase development of one of the industry's deepest and strongest pipelines of CNS products. His earlier work on Cymbalta(R) and Prozac(R) proves that he is a top-caliber scientist dedicated to developing CNS therapeutics. At MedAvante, Mike will apply his leadership abilities, scientific expertise, and commitment to quality assurance to help us deliver our leading-edge methodology for removing sources of bias and variability, increasing signal detection, and reducing the high rate of failed CNS trials."

Dr. Detke says, "MedAvante holds great promise for ensuring the future success of CNS therapeutics. For decades and now acutely, our industry has struggled with the problems of rater bias and an inability to separate placebo response from active-drug response. MedAvante offers a potential powerful solution for these problems. Our methodology to substantially increase the efficiency of clinical studies can help bring new treatments to market for patients suffering from debilitating CNS diseases. Furthermore, it can help to elucidate efficacy further, to help patients and doctors understand, for example, the relative efficacy of different drugs for a disorder, or different doses of a drug."

Prior to joining MedAvante, Dr. Detke worked for Eli Lilly Research Laboratories in Indianapolis, for more than 8 years, most recently as Executive Director overseeing all CNS products in early phase development for psychiatry, neurology and pain indications. He is Associate Clinical Professor of Psychiatry at Indiana University School of Medicine, where he teaches and supervises medical students and residents in patient care. He is Research Associate at Harvard Medical School. He has been the principal investigator in numerous studies of CNS therapeutics. Dr. Detke has published more than 50 articles in peer-reviewed journals, and has served as a reviewer for numerous such journals. He is a member in prestigious scientific organizations such as ACNP and SOBP. He graduated summa cum laude with a BA and MS in Psychology at Yale University and his MD and PhD at the University of Pennsylvania; he completed his medical internship and psychiatry residency at Harvard University.

About MedAvante, Inc

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's two-way, real-time, high-quality videoconferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, New Jersey; Los Angeles, California; and Madison, Wisconsin. MedAvante is backed by over $34 million in investor financing including $20 Million in growth financing by Goldman Sachs and Trevi Health Ventures. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jocelyn Frederick Joins Tsoi/Kobus & Associates as Principal
2. Michael J. Fox Foundation Joins Effort to Recruit 10,000 People With Parkinsons Disease to New Web-Based PD Research Community
3. Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania
4. KevinMD.com Joins the HCPLive.com Network
5. Rehab Specialist, Michael Fisher, Joins Fast - Growing Alliance Seating & Mobility in North Carolina
6. Nurse & Veteran Rehab Specialist, Terri Witten, Joins Fast-Growing Alliance Seating & Mobility in Ohio
7. Veteran Rehab Specialist, Donna Cole, Joins Fast-Growing Alliance Seating & Mobility in California
8. Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan
9. Wound Management Technologies Joins IMCO Vendor Network to Expand Sales Nationwide
10. Michael Forte Joins CONNEXION Healthcare as Chief Operations Officer
11. Julie Gallagher Joins Akerman Senterfitts Healthcare Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... Rare Disease Report®, which is the only ... Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on February ... e-newsletter and quarterly publication, will be conducting interviews with patients and advocates in ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Los Angeles-based ... episodes of WE TV’s “Mama June: From Not to Hot,” which will begin airing ... “Mama” June Shannon, known to millions from the 2012 reality television series, “Here Comes ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
(Date:2/23/2017)... ... 23, 2017 , ... Pink Pig Publishing LLC announces the ... explore the world from different perspectives. By providing a place for people of ... increase empathy, and find greater happiness. , "Our approach to structuring content ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Menopause market? What are the unit prices and annual ...
Breaking Medicine Technology: